At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 6 enrolled
Drug / intervention
Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]drug
Likely dose
Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
"Real World" Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring
In Brief
A Phase 4 clinical trial evaluating Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] for Hepatitis C and 2 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Hemodialysis, Nosocomial Infection
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartSep 2019
Primary CompletionMay 2020
Study CompletionSep 2020
TodayJul 2026
First PostedDec 7, 2017
Enrollment StartSep 22, 2019
Primary CompletionMay 1, 2020
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.6 years ago
Interventions
Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]drug
Same as described in arm description